- FAMRI Center
Lisa Bero, PhD
Professor of Clinical Pharmacy and Institute for Health Policy, UCSF
Dr. Bero is a pharmacologist with primary interest in how clinical and basic sciences are translated into clinical practice and health policy. She has developed and validated methods for assessing the quality of research and scientific publication. Lisa A. Bero, PhD, Professor, Department of Clinical Pharmacy, School of Pharmacy and Institute for Health Policy Studies, School of Medicine, University of California, San Francisco, is a pharmacologist with primary interests in how clinical and basic sciences are translated into clinical practice and health policy. She is Vice Chair in the Department of Clinical Pharmacy, and Chair of the UCSF Chancellor’s Advisory Committee on Conflicts of Interest. She has developed and validated methods for assessing the quality of research and scientific publication and measures influences on the quality of research, including university-industry relations. Dr. Bero has also conducted analyses to examine the dissemination and policy implications of scientific publications. She has published numerous peer-reviewed scientific articles related to her research as well as co-authored The Cigarette Papers (UC Press, 1996). Her international activities include: advisor to the World Health Organization Drug Action Programme and Tobacco Free Initiative. She is Co-Director of the San Francisco Branch of the United States Cochrane Center. She is a senior editor for Tobacco Control and editor for the Cochrane Effective Practice and Organization of Care Group -- an international group of researchers conducting meta-analyses of the literature on interventions to change health professional behavior. She has also been elected as a member of the Cochrane Collaboration Steering Group and serves on several national and international committees related to technology assessment.
Bachelor of Science, Physiology/Philosophy, Michigan State University, 1980 Doctor of Philosophy, Pharmacology and Toxicology, Duke University, 1987
- Lopipero, P, and Bero, L. Tobacco interests or the public interest: Twenty years of industry strategies to undermine airline smoking restrictions. Tobacco Control, 2006; 15: 323-332.
- Cook, D, and Bero, L. Identifying carcinogens: The tobacco industry and regulatory politics in the United States. Int J of Health Services, 2006; 36: 747-766.
- Prochaska, J, Hall, S, and Bero, L. Tobacco use among individuals with schizophrenia: What role has the tobacco industry played? Schizophrenia Bulletin, 2007; doi:10.1093/schbul/sbm117.
- Apollonio, DE, Lopipero, P, and Bero, L. Participation and argument in legislative debate on statewide smoking restrictions. Health Research and Policy Systems, 2007; 5: 1-11 doi:10.1186/1478-4505-5-12.
- Lopipero, P, Apollonio, DE, and Bero, L. Interest groups, lobbying and deception: The tobacco industry and airline smoking. Political Science Quarterly, Winter 2007-08; 122: 635-656.
- White, J, Parascandola, M, and Bero, L. Tobacco industry research and protection of human subjects: A case study of R.J. Reynolds. Nicotine and Tobacco Research, 2007; 9: 1213-1225.
- Apollonio, D, and Bero, L. Creating industry front groups: The tobacco industry and “Get Government Off Our Back.” American Journal of Public Health, 2007; 97: 419-427.
- Montini, T, and Bero, L. Implementation of a workplace smoking ban in bars: The limits of local discretion. BMC Public Health, 2008, 8:402 doi:10.1186/1471-2458-8-402.
- Kummerfeldt, C, Barnoya, J, and Bero, L. Philip Morris involvement in the development of an air quality laboratory in El Salvador. Tobacco Control, 2009; 18 (1) doi: 10.1136/tc.2008.026989.
- White, J, Bandura, A and Bero, L. Moral disengagement in the corporate world. Accountability in Research, 2009; 16: (1) 41 — 74 doi: 10.1080/08989620802689847.
- Montini, T, George, A, Martin-Mollard, M, and Bero, L. The role of public participation in public health initiatives: An analysis of WHO’s framework convention on tobacco control. Global Public Health, 2009; doi: 10.1080/17441690802164391.
- Odierna, D and Bero, L. Systematic reviews reveal an unrepresentative evidence base for the development of drug formularies for poor and nonwhite populations. J Clin Epidemiol, 2009; doi: 10.1016/j.jclinepi.2009.01.009.
- Cook, D, Boyd, E, Grossmann, C, and Bero, L. Journalists and conflicts of interest in science: Beliefs and practices. Ethics in Science and Environmental Politics, 2009; doi: 10.3354/esep00100.
- Cook, D, and Bero, L. The politics of smoking in federal buildings: An executive order case study, American Journal of Public Health, 2009; doi: 10.2105/AJPH.2008.151829.
- Apollonio, D, and Bero, L. Evidence and argument in policymaking: Development of workplace smoking legislation. BioMed Central Public Health, 2009; doi: 10.1186/1471-2458-9-189.
- Robertson, J, Walkom, E, Moynihan, R, Bero, L and Henry, D. Pharmaceutical industry funding of educational events for pharmacists in Australia: An analysis of data from the first 6 months of a mandatory disclosure programme. Int J Pharmacy Practice. 2010; 18: 88-92. Doi: 10.1211/ijpp/18.02.0003.
- Dhruva, S, Bero, L, Redberg, R. Strength of study evidence examined by the FDA in premarket approval of cardiovascular devices. Journal of the American Medical Association, 2009; 302(24): 2679-2685.
- Vedula, S, Bero, L, Scherer, R, Dickersin, K. Outcome reporting in industry-sponsored trials of Gabapentin for off-label use. New England Journal of Medicine, 2009; 361(20): 1963-1971.
- Robertson, J, Moynihan, R, Walkom, E, Bero, L and Henry, D. Mandatory disclosure of pharmaceutical industry funded events for health professionals. PLoS Medicine, 2009; 6(11) doi: 10.1371/journal.pmed.1000128.
- Rasmussen, N, Lee, K, Bero, L. Association of trial registration with the results and conclusions of published trails of new oncology drugs. Trials, 2009; doi:10.1186/1745-6215-10-116.
- Cook, D, Gurugubelli, RK, and Bero, L. Risk Management Policy and Black Box Warnings at the US Food and Drug Administration. Drug Safety, 2009; 32(11): 1057-1066.